These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22808029)

  • 1. 96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience.
    Capetti A; Landonio S; Meraviglia P; Di Biagio A; Lo Caputo S; Sterrantino G; Ammassari A; Menzaghi B; Franzetti M; De Socio GV; Pellicanò G; Mazzotta E; Soria A; Meschiari M; Trezzi M; Sasset L; Celesia BM; Zucchi P; Melzi S; Ricci E; Rizzardini G
    PLoS One; 2012; 7(7):e39222. PubMed ID: 22808029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of HIV-1 DNA level in highly antiretroviral-experienced patients receiving raltegravir-based therapy.
    Charpentier C; Piketty C; Laureillard D; Tisserand P; Si-Mohamed A; Weiss L; Bélec L
    Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):129-33. PubMed ID: 21559766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.
    Naumann U; Moll A; Schleehauf D; Lutz T; Schmidt W; Jaeger H; Funke B; Witte V
    Int J STD AIDS; 2017 Aug; 28(9):893-901. PubMed ID: 28385065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
    Taiwo B; Zheng L; Gallien S; Matining RM; Kuritzkes DR; Wilson CC; Berzins BI; Acosta EP; Bastow B; Kim PS; Eron JJ;
    AIDS; 2011 Nov; 25(17):2113-22. PubMed ID: 21857490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
    Pallikkuth S; Fischl MA; Pahwa S
    J Infect Dis; 2013 Nov; 208(10):1613-23. PubMed ID: 23922374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.
    Wittkop L; Breilh D; Da Silva D; Duffau P; Mercié P; Raymond I; Anies G; Fleury H; Saux MC; Dabis F; Fagard C; Thiébaut R; Masquelier B; Pellegrin I;
    J Antimicrob Chemother; 2009 Jun; 63(6):1251-5. PubMed ID: 19336453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.
    Capetti A; Meraviglia P; Landonio S; Sterrantino G; Di Biagio A; Lo Caputo S; Ammassari A; Menzaghi B; De Socio GV; Franzetti M; Soria A; Meschiari M; Sasset L; Pellicanò G; Mazzotta E; Trezzi M; Celesia BM; Melzi S; Carenzi L; Ricci E; Rizzardini G
    Int J Antimicrob Agents; 2014 Feb; 43(2):189-94. PubMed ID: 24315315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
    Caby F; Valin N; Marcelin AG; Schneider L; Andrade R; Guiguet M; Tubiana R; Canestri A; Valantin MA; Peytavin G; Pacanowski J; Morand-Joubert L; Calvez V; Girard PM; Katlama C
    Scand J Infect Dis; 2010 Jul; 42(6-7):527-32. PubMed ID: 20222846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
    Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
    Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.
    Ofotokun I; Sheth AN; Sanford SE; Easley KA; Shenvi N; White K; Eaton ME; Del Rio C; Lennox JL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1196-206. PubMed ID: 22364141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
    Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
    Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY;
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.